First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 935-942

  Bruderer, Shirin ^a   Hurst, Noémie ^a   De Kanter, Ruben ^a   Miraval, Tommaso ^a   Pfeifer, Thomas ^a   Donazzolo, Yves ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Eurofins Medinet Inc   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DRUG METABOLITE; N [4 (4 ACETYLPIPERAZIN 1 YL)BENZYL] 3 [4 (TERT-BUTYL)PHENYL] N [1 [4 (4 CYANOBENZYL)PIPERAZIN 1 YL] 1 OXO 3 PHENYLPROPAN 2 YL]ACRYLAMIDE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; FIRST IN HUMAN STUDY; FOOD; FOOD DRUG INTERACTION; HUMAN; IC50; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TONSILLITIS; ADOLESCENT; CLINICAL TRIAL; ELECTROCARDIOGRAPHY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84921899077     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04125-14     Document Type: Article

References (25)

1. World Health Organization (WHO). 2008. Global malaria action plan, for a malaria-free world. World Health Organization, Geneva, Switzerland. http://www.rollbackmalaria.org/gmap/gmap.pdf.
2. World Health Organization (WHO). 2012. WHO, world malaria report 2012. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria /publications/world-malaria-report-2012/wmr2012-no-profiles.pdf?ua=1.
3. Noor AM, Kinyoki DK, Mundia CW, Kabaria CW, Mutua JW, Alegana VA, Fall IS, Snow RW. 2014. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. Lancet 383:1739-1747. http://dx.doi.org/10.1016 /S0140-6736(13)62566-0.
4. World Health Organization (WHO). 2012. Global malaria program: update on artemisinin resistance, April 2012. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/atoz/arupdate042012 .pdf?ua = 1.
5. World Health Organization (WHO). 2012. Emergency response to artemisinin resistance in the greater Mekong subregion: regional framework for action 2013-2015. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris /bitstream/10665/79940/1/9789241505321-eng.pdf?ua = 1.
6. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL, Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE, Cardon LR, Garcia-Bustos JF. 2010. Thousands of chemical starting points for antimalarial lead identification. Nature 465:305-310. http://dx .doi.org/10.1038/nature09107.
7. Brunner R, Aissaoui H, Boss C, Bozdech Z, Brun R, Corminboeuf O, Delahaye S, Fischli C, Heidmann B, Kaiser M, Kamber J, Meyer S, Papastogiannidis P, Siegrist R, Voss T, Welford R, Wittlin S, Binkert C. 2012. Identification of a new chemical class of antimalarials. J Infect Dis 206:735-743. http://dx.doi.org/10.1093/infdis/jis418.
8. Janse CJ, Waters AP, Kos J, Lugt CB. 1994. Comparison of in vivo and in vitro antimalarial activity of artemisinin, dihydroartemisinin and sodium artesunate in the Plasmodium berghei-rodent model. Int J Parasitol 24: 589-594. http://dx.doi.org/10.1016/0020-7519(94)90150-3.
9. European Medicines Agency 2002. ICH topic E 6 (R1): guideline for good clinical practice. European Medicines Agency, London, United Kingdom.
10. U.S. Food and Drug Administration. 2005. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Rockville, MD. http://www.fda.gov/downloads /Drugs/Guidances/UCM078932.pdf.
11. U.S. Food and Drug Administration. 2002. Guidance for industry: foodeffect bioavailability and, fed bioequivalence studies. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), Rockville, MD. http://www.fda .gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf.
12. Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. 1995. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokineticsUKjoint working party. Drug Inform J 29:1039-1048.
13. Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forque ST. 2000. Confidence interval criteria for assessment of dose proportionality. Pharm Res 17:1278-1283. http://dx.doi.org/10.1023/A:1026451721686.
14. Teja-Isavadharm P, Peggins JO, Brewer TG, White NJ, Webster HK, Kyle DE. 2004. Plasmodium falciparum-based bioassay for measurement of artemisinin derivatives in plasma or serum. Antimicrob Agents Chemother 48:954-960. http://dx.doi.org/10.1128/AAC.48.3.954-960.2004.
15. Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, Charman SA, Gutierrez M, Wittlin S, Vennerstrom JL. 2013. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol 75:524-537. http://dx.doi.org/10.1111 /j.1365-2125.2012.04368.x.
16. Hamilton RA, Garnett WR, Kline BJ. 1981. Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408-413. http://dx.doi.org/10.1038/clpt.1981.56.
17. Winstanley PA, Orme ML. 1989. The effect of food on drug bioavailability. Br J Clin Pharmacol 28:621-628. http://dx.doi.org/10.1111/j.1365 -2125.1989.tb03554.x.
18. Sugano K, Kataoka M, Mathews Cda C, Yamashita S. 2010. Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid. Eur J Pharm Sci 40:118-124. http://dx.doi.org /10.1016/j.ejps.2010.03.011.
19. Ashley EA, Stepniewska K, Lindegårdh N, Annerberg A, Kham A, Brockman A, Singhasivanon P, White NJ, Nosten F. 2007. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health 12:195-200. http://dx.doi.org/10.1111/j.1365-3156.2006.01784.x.
20. Djimdé A, Lefèvre G. 2009. Understanding the pharmacokinetics of Coartem. Malar J 8:1-8. http://dx.doi.org/10.1186/1475-2875-8-1.
21. Memvanga PB, Préat V. 2012. Formulation design and in vivo antimalarial evaluation of lipid-based drug delivery systems for oral delivery of -arteether. Eur J Pharm Biopharm 82:112-119. http://dx.doi.org/10 .1016/j.ejpb.2012.05.004.
22. Holm R, Tønsberg H, Jørgensen EB, Abedinpour P, Farsad S, Müllertz A. 2012. Influence of bile on the absorption of halofantrine from lipidbased formulations. Eur J Pharm Biopharm 81:281-287. http://dx.doi.org /10.1016/j.ejpb.2012.03.005.
23. Vyas N, Avery BA, Avery MA, Wyandt CM. 2002. Carrier-mediated partitioning of artemisinin into Plasmodium falciparum-infected erythrocytes. Antimicrob Agents Chemother 46:105-109. http://dx.doi.org/10 .1128/AAC.46.1.105-109.2002.
24. Pooley S, Fatih FA, Krishna S, Gerisch M, Haynes RK, Wong HN, Staines HM. 2011. Artemisone uptake in Plasmodium falciparum-infected erythrocytes. Antimicrob Agents Chemother 55:550-556. http://dx.doi .org/10.1128/AAC.01216-10.
25. San George RC, Nagel RL, Fabry ME. 1984. On the mechanism for the red cell accumulation of mefloquine, an antimalarial drug. Biochim Biophys Acta 803:174-181. http://dx.doi.org/10.1016/0167-4889(84)90007-7.